Conférence

Notice

Langue :

Anglais

Crédits

Université de Bordeaux - Service Audiovisuel et Multimédia (Production), Université de Bordeaux - Service Audiovisuel et Multimédia (Publication), Université de Bordeaux - Service Audiovisuel et Multimédia (Réalisation), François-Xavier Mahon (Intervention)

Conditions d'utilisation

Creative Commons (BY NC)

DOI : 10.60527/213y-wx88

Citer cette ressource :

François-Xavier Mahon. Univ Bordeaux. (2014, 7 novembre). Curing leukemia ? , in BRIO SIRIC scientific day 2. [Vidéo]. Canal-U. https://doi.org/10.60527/213y-wx88. (Consultée le 19 juillet 2025)

Curing leukemia ?

Réalisation : 7 novembre 2014 - Mise en ligne : 18 décembre 2014

document 1 document 2 document 3
niveau 1 niveau 2 niveau 3

Descriptif

Non-pharmaceutical medical innovations and public health

The use of tyrosine kinase inhibitors (TKIs) targeted against the BCR-ABL1 oncoprotein has proven remarkably successful in chronic myeloid leukemia (CML) and long-term survival has become a reality. Despite this outstanding progress, detection of minimal residual disease precludes therapy termination in most TKI-receiving patients. CML has thus turned into a chronic illness, raising concerns about long-term safety, medication adherence and healthcare costs. Although treatment cessation may be feasible in few selected patients achieving deep molecular responses, a definitive cure remains elusive owing to the discovery that TKIs spare quiescent leukemic stem cells (LSC). Understanding mechanisms underlying LSC behavior in TKI-treated patients may provide important clues to develop an array of strategies that ensure the complete destruction of LSC reservoirs and thereby offer CML patients a definitive cure.

Cette présentation a été donnée dans le cadre du ScientificBRIO Day 2 organisé annuellement par le SIRIC BRIO et qui a pour but de réunirtous les acteurs du SIRIC BRIO et plus largement de la cancérologie à Bordeaux.

Intervention

Mahon

François-Xavier

Docteur en médecine (Poitiers, 1993). Praticien Hospitalier. Maître de Conférences en Hématologie à l'Université Bordeaux 2 (en 2001)

Thème

Disciplines :

Dans la même collection

Conférence

00:13:08

Favoris
Multisarc
ITALIANO Antoine
Translational science : how to move from biology to clinical applications Soft-tissues sarcomas represent an heterogeneous group of tumors. Stadard of care is surgical resection followed by
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:13:01

Favoris
BRIO's facts and figures, structuration projects : Axe Cancer, translational research centerUpdate …
SOUBEYRAN Pierre
Update the implementation of BRIO Brio organisation is now fully up and running, and more than 100 research projects are currently active into the 6 integrated research programmes. In addition,
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:15:00

Favoris
Standardizing G8 evaluation
SOUBEYRAN Pierre
Non-pharmaceutical innovations and public health Management of the frail elderly with cancer is a challenge. Beside a poor outcome as compared to younger subjects, physicians will face increased
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:16:54

Favoris
Bordeaux Cancer Initiative
DESSIS Damien

ELUSTONDO Frédéric
Translational science : how to move from biology to clinical applications Upon request of the University, the SIRIC was mandated to develop a transversal cancer axis at the University. The axis
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:18:28

Favoris
Sociology contribution to understanding the (no)diffusion of a medical innovation
GORRY Philippe
Interface technology/clinical/SHS/public health : case study interventional radiology We will present results of an undergoing study on the socioeconomic processes of recognition in oncology of a
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:29:16

Favoris
Translational cancer genomics and proteomics
SLEIJFER Stefan
Translational science : how to move from biology to clinical applications Evaluation of cell-free DNA (cfDNA) is a very attractive tool to serve as “liquid biopsy” to define and establish
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

01:00:29

Favoris
Expert panel discussions : why translational research matters
CAMERON David
En point d'orgue du Scientific BRIO Day, David Cameron, spécialiste reconnu en Oncologie, Professeur à l'Université d'Edimbourg, anime un débat sur la question de la recherche dite translationnelle,
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:09:10

Favoris
Innovation reimbursement
FILLATREAU Christian
Interface technology/clinical/SHS/public health : case study interventional radiology Novel diagnostic and therapeutic strategies is a continuum of 3 strongly associated phases : clinical
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:18:23

Favoris
A new preclinical model to test the response of breast cancer to genomically targeted therapy
IGGO Richard
Translational science : how to move from biology to clinical applications The rapid progress in next generation DNA sequencing technology (NGS) means it is now possible, in principle, to obtain a
Cancer
Oncologie
Therapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3
Conférence

00:22:10

Favoris
Technique, research and benefits
GRENIER Nicolas

PALUSSIèRE Jean
Interface technology/clinical/SHS/public health : case study interventional radiology
Cancer
Oncologie
Thérapie
Recherche
18.12.2014
document 1 document 2 document 3
niveau 1 niveau 2 niveau 3